Clinical efficacy and safety evaluation of enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension
10.13699/j.cnki.1001-6821.2015.16.001
- VernacularTitle:依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性评价
- Author:
Hai-Ning SONG
1
;
Hai-Yan LAI
;
Qian LI
Author Information
1. 成都市第三人民医院药剂科
- Keywords:
enalapril;
irbesartan;
hydrochlorothiazide;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1563-1565
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension.Methods Sixty -nine patients with moderate to severe essential hypertension were randomly divided into control group ( n=34) with enalapril 10 mg +hydrochlorothiazide 12.5 mg orally bid and treatment group ( n =35 ) with irbesartan 50 mg +hydrochlorothiazide 12.5 mg orally bid with 2 months.After treatment, the clinical efficacy, serum level of creatinine, acidum uricum and potassium and the ratio of adverse event were compared between the two groups. Results After 2 months treatment, the blood pressure was significant decreased in control and treatment groups. The clinical efficacy were 88.24% and 88.57% with not statistical difference ( P >0.05 ) .The serum level of creatinine, acidum uricum and potassium had no obvious difference before and after the treatment in the two groups (P>0.05).Four cases of cough were observed in the control group and the treatment group, respectively, without statistical difference (P>0.05).Conclusion There was no clinical efficacy difference for enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension.But irbesartan combined with hydrochlorothiazide had less cough adverse event.
